Company profile: Akero Therapeutics
1.1 - Company Overview
Company description
- Provider of investigational therapies for metabolic dysfunction-associated steatohepatitis (MASH), including efruxifermin (EFX), which mimics FGF21 to regulate metabolic pathways and cellular processes; clinical trials (SYNCHRONY, SYMMETRY, HARMONY, BALANCED) evaluating EFX; pipeline development for MASH and other serious metabolic diseases; and manufacturing partnerships with Boehringer-Ingelheim and Vetter Pharma.
Products and services
- Clinical Trials: MASH-specific studies, including SYNCHRONY, SYMMETRY, HARMONY, and BALANCED, evaluating EFX’s safety and efficacy in patients through ongoing and completed clinical assessments
- Efruxifermin (EFX): FGF21-mimetic investigational drug for MASH, architected to regulate multiple metabolic pathways and cellular processes implicated in metabolic dysfunction-associated steatohepatitis
- Manufacturing Partnerships: API-grade collaborations with Boehringer-Ingelheim and Vetter Pharma delivering high-quality active pharmaceutical ingredients and drug products to support EFX development and supply
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Akero Therapeutics
USGI Medical
HQ: United States
Website
- Description: Provider of incisionless surgical technologies for gastrointestinal procedures, offering the Incisionless Operating Platform to address GI procedural challenges; the POSE2.0 endoscopic gastroplasty using Snowshoe Suture Anchors to provide gastric restriction without removing part of the stomach; and tools including the g-Cath Tissue Anchor Delivery Catheter, g-Prox EZ Endoscopic Grasper, and Transport Endoscopic Guide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full USGI Medical company profile →
OrsoBio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for severe metabolic disorders, including TLC-3595 (selective ACC2 inhibitor) to improve insulin sensitivity in type 2 diabetes; TLC-2716 (liver-targeted LXR inverse agonist) to lower plasma triglycerides and cholesterol in severe dyslipidemias; mitochondrial protonophores (TLC-6740, TLC-1235) to increase energy expenditure; and an ACMSD inhibitor to augment NAD+ and mitochondrial function in liver/kidney dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OrsoBio company profile →
Jecure Therapeutics
HQ: United States
Website
- Description: Provider of research and development focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jecure Therapeutics company profile →
Corline Biomedical
HQ: Sweden
Website
- Description: Provider of heparin-based solutions to improve kidney transplantation, cell therapies and regenerative medicine. Offers Renaparin to enhance kidney transplant outcomes and Cytoparin for cell therapies and treatment of type 1 diabetes, using proprietary heparin technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corline Biomedical company profile →
Altimmune
HQ: United States
Website
- Description: Provider of vaccines and other biological products to address unmet market and public health needs, using proprietary non-invasive intranasal delivery to stimulate robust and durable immune responses for prevention; programs include pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). Proof of principle shown in animals and initial human clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altimmune company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Akero Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Akero Therapeutics
2.2 - Growth funds investing in similar companies to Akero Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Akero Therapeutics
4.2 - Public trading comparable groups for Akero Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →